Thromboprophylaxis in the oldest old with atrial fibrillation: Between Scylla and Charybdis

European Journal of Internal Medicine

Volumn 24, Issue 4, 2013, Pages 285-287

  Mannucci, Pier Mannuccio ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Apixaban; Atrial fibrillation; Dabigatran etexilate; Rivaroxaban; Vitamin K antagonists

Indexed keywords

APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; COGNITIVE DEFECT; HEART ATRIUM FIBRILLATION; HUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POLYPHARMACY; REVIEW; RISK ASSESSMENT; THROMBOEMBOLISM; THROMBOSIS PREVENTION;

AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; FIBRINOLYTIC AGENTS; HUMANS; MEDICATION ADHERENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; THROMBOEMBOLISM; VITAMIN K;

EID: 84878276945     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2013.02.001     Document Type: Review

References (18)

1. A.S. Go, E.M. Hylek, K.A. Phillips, Y. Chang, L.E. Henault, and J.V. Selby Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study JAMA 285 2001 2370 2375
2. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation as an independent risk factor for stroke: the Framingham Study Stroke 22 1991 983 988
3. G. Saposnik, S.E. Black, A. Hakim, J. Fang, J.V. Tu, and M.K. Kapral Age disparities in stroke quality of care and delivery of health services Stroke 40 2009 3328 3335
4. A.S. Go, E.M. Hylek, L.H. Borowsky, K.A. Phillips, J.V. Selby, and D.E. Singer Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study Ann Intern Med 131 1999 927 934
5. D. Poli, E. Antonucci, S. Testa, A. Tosetto, W. Ageno, and G. Palareti Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation Circulation 124 2011 824 829
6. M. Marcucci, A. Iorio, A. Nobili, M. Tettamanti, L. Pasina, and A. Marengoni Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards Eur J Intern Med 21 2010 516 523
7. C. van Walraven, R.G. Hart, S. Connolly, P.C. Austin, J. Mant, and F.D. Hobbs Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators Stroke 40 2009 1410 1416
8. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, and A. Parekh Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
9. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, and W. Hacke Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
10. C.B. Granger, J.H. Alexander, J.J. McMurray, R.D. Lopes, E.M. Hylek, and M. Hanna Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
11. P.M. Mannucci, A. Nobili, and S. Garattini New drugs for thromboprophylaxis in atrial fibrillation Eur J Intern Med 23 2012 1 5
12. V. Pengo, L. Crippa, A. Falanga, G. Finazzi, F. Marongiu, and M. Moia Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results J Thromb Haemost 10 2012 1979 1987
13. P.R. Sinnaeve, M. Brueckmann, A. Clemens, J. Oldgren, J. Eikelboom, and J.S. Healey Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation J Intern Med 271 2012 15 24
14. J.W. Eikelboom, L. Wallentin, S.J. Connolly, M. Ezekowitz, J.S. Healey, and J. Oldgren Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial Circulation 123 2011 2363 2372
15. J.W. Coppens, M. Eikelboom, A. Ezekowitz, J. Clemens, L. Healy, and H. Wallentin Dabigatran versus warfarin in very elderly patients with atrial fibrillation: results from the RE-LY trial Circulation 126 2012 A15537
16. R.D. Lopes, S.M. Al-Khatib, L. Wallentin, H. Yang, J. Ansell, and M.C. Bahit Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomized controlled trial Lancet 380 2012 1749 1758
17. D. Poli, E. Antonucci, M. Zanazzi, E. Grifoni, S. Testa, and W. Ageno Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists. Results of EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics) Thromb Haemost 107 2012 1100 1106
18. B. Vrijens, G. Vincze, P. Kristanto, J. Urquhart, and M. Burnier Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories BMJ 336 2008 1114 1117